PL4058474T3 - Kompozycje i sposoby leczenia nowotworów egfr-dodatnich - Google Patents

Kompozycje i sposoby leczenia nowotworów egfr-dodatnich

Info

Publication number
PL4058474T3
PL4058474T3 PL21769291.2T PL21769291T PL4058474T3 PL 4058474 T3 PL4058474 T3 PL 4058474T3 PL 21769291 T PL21769291 T PL 21769291T PL 4058474 T3 PL4058474 T3 PL 4058474T3
Authority
PL
Poland
Prior art keywords
egfr
compositions
treatment
methods
positive cancer
Prior art date
Application number
PL21769291.2T
Other languages
English (en)
Inventor
Julyun OH
Han Xu
Carl Alexander Kamb
Original Assignee
A2 Biotherapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by A2 Biotherapeutics, Inc. filed Critical A2 Biotherapeutics, Inc.
Publication of PL4058474T3 publication Critical patent/PL4058474T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/4203—Receptors for growth factors
    • A61K40/4204—Epidermal growth factor receptors [EGFR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0693—Tumour cells; Cancer cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/11—Epidermal growth factor [EGF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/515—CD3, T-cell receptor complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
PL21769291.2T 2020-08-20 2021-08-19 Kompozycje i sposoby leczenia nowotworów egfr-dodatnich PL4058474T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202063068249P 2020-08-20 2020-08-20
US202063105639P 2020-10-26 2020-10-26
US202163230632P 2021-08-06 2021-08-06
PCT/US2021/046733 WO2022040444A1 (en) 2020-08-20 2021-08-19 Compositions and methods for treating egfr positive cancers

Publications (1)

Publication Number Publication Date
PL4058474T3 true PL4058474T3 (pl) 2024-09-23

Family

ID=77711489

Family Applications (1)

Application Number Title Priority Date Filing Date
PL21769291.2T PL4058474T3 (pl) 2020-08-20 2021-08-19 Kompozycje i sposoby leczenia nowotworów egfr-dodatnich

Country Status (21)

Country Link
US (2) US11602544B2 (pl)
EP (2) EP4058474B1 (pl)
JP (2) JP7621461B2 (pl)
KR (1) KR20230052289A (pl)
AU (1) AU2021328478A1 (pl)
BR (1) BR112023002668A2 (pl)
CA (1) CA3189510A1 (pl)
DK (1) DK4058474T3 (pl)
ES (1) ES2984902T3 (pl)
FI (1) FI4058474T3 (pl)
HR (1) HRP20240903T1 (pl)
HU (1) HUE067417T2 (pl)
IL (1) IL300629A (pl)
LT (1) LT4058474T (pl)
MX (1) MX2023002104A (pl)
PL (1) PL4058474T3 (pl)
PT (1) PT4058474T (pl)
RS (1) RS65802B1 (pl)
SI (1) SI4058474T1 (pl)
TW (1) TW202214846A (pl)
WO (1) WO2022040444A1 (pl)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT4058474T (pt) 2020-08-20 2024-07-09 A2 Biotherapeutics Inc Composições e métodos para tratamento de cancros positivos para egfr
AU2024317321A1 (en) * 2023-08-02 2026-02-12 A2 Biotherapeutics, Inc. Compositions and methods for treating cancers with hla-a*03 loss of expression
WO2025085867A1 (en) * 2023-10-20 2025-04-24 A2 Biotherapeutics, Inc. Compositions and methods for treating blood cancers
WO2025085846A1 (en) * 2023-10-20 2025-04-24 A2 Biotherapeutics, Inc. Engineered interleukins and uses thereof

Family Cites Families (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4690915A (en) 1985-08-08 1987-09-01 The United States Of America As Represented By The Department Of Health And Human Services Adoptive immunotherapy as a treatment modality in humans
US6534055B1 (en) 1988-11-23 2003-03-18 Genetics Institute, Inc. Methods for selectively stimulating proliferation of T cells
US5858358A (en) 1992-04-07 1999-01-12 The United States Of America As Represented By The Secretary Of The Navy Methods for selectively stimulating proliferation of T cells
US6905680B2 (en) 1988-11-23 2005-06-14 Genetics Institute, Inc. Methods of treating HIV infected subjects
US6352694B1 (en) 1994-06-03 2002-03-05 Genetics Institute, Inc. Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells
US5585362A (en) 1989-08-22 1996-12-17 The Regents Of The University Of Michigan Adenovirus vectors for gene therapy
US5350674A (en) 1992-09-04 1994-09-27 Becton, Dickinson And Company Intrinsic factor - horse peroxidase conjugates and a method for increasing the stability thereof
US7175843B2 (en) 1994-06-03 2007-02-13 Genetics Institute, Llc Methods for selectively stimulating proliferation of T cells
US7067318B2 (en) 1995-06-07 2006-06-27 The Regents Of The University Of Michigan Methods for transfecting T cells
US6692964B1 (en) 1995-05-04 2004-02-17 The United States Of America As Represented By The Secretary Of The Navy Methods for transfecting T cells
EP1235842A4 (en) 1999-10-15 2003-04-23 Univ Massachusetts Rna interference pathway genes as tools for targeted genetic interference
US6326193B1 (en) 1999-11-05 2001-12-04 Cambria Biosciences, Llc Insect control agent
US6867041B2 (en) 2000-02-24 2005-03-15 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
US7572631B2 (en) 2000-02-24 2009-08-11 Invitrogen Corporation Activation and expansion of T cells
ATE373078T1 (de) 2000-02-24 2007-09-15 Xcyte Therapies Inc Gleichzeitige stimulation und konzentration von zellen
US6797514B2 (en) 2000-02-24 2004-09-28 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
WO2001096584A2 (en) 2000-06-12 2001-12-20 Akkadix Corporation Materials and methods for the control of nematodes
US7745140B2 (en) 2002-01-03 2010-06-29 The Trustees Of The University Of Pennsylvania Activation and expansion of T-cells using an engineered multivalent signaling platform as a research tool
US20030170238A1 (en) 2002-03-07 2003-09-11 Gruenberg Micheal L. Re-activated T-cells for adoptive immunotherapy
EP2514758B2 (en) 2004-03-15 2021-06-23 City of Hope Methods and compositions for the specific inhibition of gene expression by double-stranded RNA
EP2332990A1 (en) 2004-03-19 2011-06-15 Imclone LLC Human anti-epidermal growth factor receptor antibody
AU2005250408B2 (en) 2004-05-27 2010-09-23 The Trustees Of The University Of Pennsylvania Novel artificial antigen presenting cells and uses therefor
CN104159909A (zh) 2012-02-22 2014-11-19 宾夕法尼亚大学董事会 产生用于癌症治疗的t细胞持续性群体的组合物和方法
RS59199B1 (sr) 2012-05-25 2019-10-31 Univ California Metode i jedinjenja za rnk-upravljanu ciljanu dnk modifikaciju i za rnk- upravljanu modulaciju transkripta
US20150183877A1 (en) * 2012-07-18 2015-07-02 Eli Lilly And Company Multi-Specific IgG-(Fab)2 Constructs Containing T-Cell Receptor Constant Domains
IL300461A (en) 2012-12-12 2023-04-01 Harvard College Engineering and optimization of improved systems, methods and enzyme compositions for sequence manipulation
US8697359B1 (en) 2012-12-12 2014-04-15 The Broad Institute, Inc. CRISPR-Cas systems and methods for altering expression of gene products
EP3825401A1 (en) 2012-12-12 2021-05-26 The Broad Institute, Inc. Crispr-cas component systems, methods and compositions for sequence manipulation
EP2970426B1 (en) 2013-03-15 2019-08-28 Michael C. Milone Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
MX386060B (es) 2013-03-15 2025-03-18 Memorial Sloan Kettering Cancer Center Composiciones y usos para inmunoterapia.
DK3027204T3 (da) 2013-07-29 2022-04-19 2Seventy Bio Inc Flerdelte signaleringsproteiner og anvendelser deraf
HUE051523T2 (hu) 2013-11-21 2021-03-01 Ucl Business Ltd Sejt
JP2017505819A (ja) 2014-02-04 2017-02-23 カイト ファーマ インコーポレイテッドＫｉｔｅ Ｐｈａｒｍａ， Ｉｎｃ Ｂ細胞悪性腫瘍及び他のがんの治療に有用な自己ｔ細胞を産生する方法、並びにその組成物
EP3116902B1 (en) * 2014-03-11 2020-01-01 Cellectis Method for generating t-cells compatible for allogenic transplantation
AU2015344769B2 (en) 2014-11-12 2020-07-09 Allogene Therapeutics, Inc. Inhibitory chimeric antigen receptors
AU2015367317A1 (en) 2014-12-17 2017-06-01 Cellectis Inhibitory chimeric antigen receptor (iCAR or N-CAR) expressing non-T cell transduction domain
WO2016126608A1 (en) 2015-02-02 2016-08-11 Novartis Ag Car-expressing cells against multiple tumor antigens and uses thereof
JP6784687B2 (ja) 2015-02-24 2020-11-11 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 結合誘発型転写スイッチ及びその使用方法
US11186824B2 (en) 2015-03-11 2021-11-30 Cellectis Methods for engineering allogeneic T cell to increase their persistence and/or engraftment into patients
JP6843062B2 (ja) 2015-03-27 2021-03-17 ユニバーシティ オブ サザン カリフォルニア Ｃａｒ ｔ細胞免疫療法のための新規標的としてのｈｌａ−ｇ
GB201509413D0 (en) 2015-06-01 2015-07-15 Ucl Business Plc Fusion protein
MA42895A (fr) 2015-07-15 2018-05-23 Juno Therapeutics Inc Cellules modifiées pour thérapie cellulaire adoptive
MA44314A (fr) 2015-11-05 2018-09-12 Juno Therapeutics Inc Récepteurs chimériques contenant des domaines induisant traf, et compositions et méthodes associées
WO2017087723A1 (en) 2015-11-19 2017-05-26 The Regents Of The University Of California Conditionally repressible immune cell receptors and methods of use thereof
EP3380602A4 (en) 2015-11-23 2019-09-25 Trustees of Boston University METHOD AND COMPOSITIONS RELATED TO CHIMERIC ANTIGEN RECEPTORS
AU2016363696B2 (en) 2015-12-02 2021-05-20 Innovative Targeting Solutions Inc. Single variable domain T-cell receptors
AU2017230011A1 (en) 2016-03-11 2018-09-27 2Seventy Bio, Inc. Genome edited immune effector cells
CA3029121A1 (en) 2016-06-29 2018-01-04 Crispr Therapeutics Ag Compositions and methods for gene editing
EP3263595A1 (en) 2016-06-30 2018-01-03 Medizinische Hochschule Hannover Fusion protein for use in the treatment of hvg disease
EP3519564B1 (en) 2016-09-28 2023-11-15 Gavish-Galilee Bio Applications Ltd A universal platform for car therapy targeting a novel antigenic signature of cancer
JP2020506700A (ja) 2017-01-31 2020-03-05 ノバルティス アーゲー 多重特異性を有するキメラｔ細胞受容体タンパク質を用いた癌の治療
EP3579877A4 (en) 2017-02-09 2020-12-09 The Regents of The University of California CHEMERIC T-LYMPHOCYTE ANTIGENIC RECEPTORS AND METHODS OF USE
AU2018270078A1 (en) 2017-05-15 2019-11-07 Autolus Limited A cell comprising a chimeric antigen receptor (CAR)
GB201707779D0 (en) 2017-05-15 2017-06-28 Autolus Ltd Cell
GB201707783D0 (en) 2017-05-15 2017-06-28 Autolus Ltd Cell
KR102742220B1 (ko) 2017-09-19 2024-12-17 더 유니버시티 오브 브리티쉬 콜롬비아 항-hla-a2 항체 및 그 사용 방법
FI3688155T3 (fi) 2017-09-28 2023-03-30 Immpact Bio Ltd Universaali alusta inhibitorisen kimeerisen antigeenireseptorin (icar) valmistamiseksi
EP3707166A4 (en) 2017-11-06 2021-11-24 Daniel J. Monticello CHEMICAL ANTIGENIC RECEPTOR SYSTEMS WITH NEGATIVE DOMINANT LIGAND
WO2019241549A1 (en) 2018-06-15 2019-12-19 A2 Biotherapeutics, Inc. Foxp3-expressing car-t regulatory cells
EP3856236B1 (en) 2018-09-28 2023-05-17 ImmPACT-Bio Ltd. Methods for identifying activating antigen receptor (acar)/inhibitory chimeric antigen receptor (icar) pairs for use in cancer therapies
EP3860643A1 (en) 2018-10-05 2021-08-11 St. Anna Kinderkrebsforschung A group of chimeric antigen receptors (cars)
EP3632461A1 (en) 2018-10-05 2020-04-08 St. Anna Kinderkrebsforschung A group of chimeric antigen receptors (cars)
CR20210628A (es) 2019-06-26 2022-03-22 Amunix Pharmaceuticals Inc Fragmentos de unión al antígeno cd3 y composiciones que comprenden los mismos
WO2021030153A2 (en) 2019-08-09 2021-02-18 A2 Biotherapeutics, Inc. Engineered t cell receptors and uses thereof
BR112022002465A2 (pt) * 2019-08-09 2022-05-03 A2 Biotherapeutics Inc Receptores de superfície celular responsivos à perda de heterozigosidade
WO2021030182A1 (en) 2019-08-09 2021-02-18 A2 Biotherapeutics, Inc. Bifunctional single variable domain t cell receptors and uses thereof
EP4017510A4 (en) 2019-08-20 2023-11-22 Senti Biosciences, Inc. CHIMERIC INHIBITOR RECEPTOR
EP4058561A1 (en) 2019-11-12 2022-09-21 A2 Biotherapeutics, Inc. Engineered t cell receptors and uses thereof
WO2021119489A1 (en) 2019-12-11 2021-06-17 A2 Biotherapeutics, Inc. Lilrb1-based chimeric antigen receptor
WO2021222576A1 (en) 2020-05-01 2021-11-04 A2 Biotherapeutics, Inc. Pag1 fusion proteins and methods of making and using same
PT4058474T (pt) 2020-08-20 2024-07-09 A2 Biotherapeutics Inc Composições e métodos para tratamento de cancros positivos para egfr

Also Published As

Publication number Publication date
JP2023538116A (ja) 2023-09-06
RS65802B1 (sr) 2024-08-30
SI4058474T1 (sl) 2024-09-30
JP7621461B2 (ja) 2025-01-24
CA3189510A1 (en) 2022-02-24
HRP20240903T1 (hr) 2024-10-11
US20230277593A1 (en) 2023-09-07
EP4058474B1 (en) 2024-05-08
JP2024159820A (ja) 2024-11-08
HUE067417T2 (hu) 2024-10-28
PT4058474T (pt) 2024-07-09
ES2984902T3 (es) 2024-10-31
US11602544B2 (en) 2023-03-14
EP4442815A2 (en) 2024-10-09
IL300629A (en) 2023-04-01
LT4058474T (lt) 2024-08-26
AU2021328478A1 (en) 2023-04-20
TW202214846A (zh) 2022-04-16
KR20230052289A (ko) 2023-04-19
MX2023002104A (es) 2023-07-10
FI4058474T3 (fi) 2024-07-01
EP4442815A3 (en) 2025-01-01
EP4058474A1 (en) 2022-09-21
BR112023002668A2 (pt) 2023-05-02
WO2022040444A1 (en) 2022-02-24
DK4058474T3 (da) 2024-07-22
US20220273721A1 (en) 2022-09-01

Similar Documents

Publication Publication Date Title
PL4058474T3 (pl) Kompozycje i sposoby leczenia nowotworów egfr-dodatnich
IL288395A (en) Mat2a tricyclic inhibitors and methods for use in cancer therapy
IL300067A (en) Preparations and methods for the treatment of cancers
BR112018070163A2 (pt) compostos de aminopurina substituída, composições e métodos de tratamento
EP4319751A4 (en) THERAPEUTIC COMPOSITIONS AND METHODS FOR THE TREATING OF TUMORS
IL308766A (en) Compositions and methods for treating prostate cancer
EP4121077A4 (en) COMPOSITIONS AND METHODS FOR TREATING SOLID AND SOFT TUMORS AND PROLIFERATIVE DISEASES
EP4319741A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER
EP4110822A4 (en) COMPOSITIONS AND METHODS FOR TREATING CANCER
BR112019006329A2 (pt) métodos de tratamento de câncer do trato biliar
IL304467A (en) Pharmaceutical compositions for the treatment of breast cancer and methods of using them
EP4440623A4 (en) Polytherapy for the treatment of cancer
EP4294828A4 (en) COMPOSITIONS AND METHODS FOR THE TREATING HER2-POSITIVE CANCERS
IL309662A (en) Compositions and methods for treating cancers
PL4153232T3 (pl) TERAPIA IMMUNOKONIUGATEM TNF-α DO LECZENIA GUZÓW MÓZGU
IL315800A (en) Preparations and methods for the treatment of cancer
EP4384220A4 (en) Compositions and methods for treatment of cancer
IL309120A (en) Methods and compositions for the treatment of cancer
EP4370921A4 (en) COMPOSITIONS AND METHODS FOR IMPROVING CANCER TREATMENT
IL287538A (en) Preparations and methods for the treatment of cancer
IL288787A (en) Methods and preparations to improve results in cancer patients
EP4244390A4 (en) COMPOSITIONS AND METHODS FOR IDENTIFYING, EVALUATING AND TREATING A CANCER PATIENT
IL308133A (en) Compositions and methods for treating neuroendocrine tumors
EP3987032A4 (en) Methods and compositions for the treatment of cancer
IL312844A (en) Methods and compositions for treating cancer